10-KPeriod: FY2011

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2011

Filed February 16, 2012For Securities:DGX

Summary

Quest Diagnostics Inc.'s 2011 10-K filing reveals a mixed financial performance, with net revenues showing a slight increase driven by strategic acquisitions, but a significant decline in income from continuing operations. The company finalized the acquisitions of Athena Diagnostics and Celera Corporation, which contributed to revenue growth but also incurred transaction costs. A substantial pre-tax charge of $236 million related to the settlement of a California lawsuit significantly impacted profitability in 2011. Despite operational challenges and significant one-time charges, the company is focused on long-term growth through investments in technology and innovation, alongside cost-reduction initiatives aimed at improving operating efficiency. Financially, while net revenues grew by 1.9% to $7.51 billion, income from continuing operations dropped by 34.7% to $472.1 million. This was largely due to the aforementioned lawsuit settlement, restructuring charges, and increased operating expenses related to employee compensation and investments in sales and service capabilities. The company's balance sheet shows an increase in total assets and total debt, reflecting the acquisitions and related financing. Shareholder returns remain a focus, with an increased dividend declared and ongoing share repurchase programs.

Financial Highlights

57 data points
Beta

Revenue

$7.39B

41.0% Gross Margin

Net Income

$471.00M

6.4% Net Margin

EPS (Diluted)

$2.92

Total Assets

$9.31B

Cash & Equivalents

$165.00M

Free Cash Flow

$734.00M

Financial Statements
Beta
Revenue$7.39B
Cost of Revenue$4.36B
Gross Profit$3.03B
SG&A Expenses$1.74B
Operating Expenses$6.41B
Operating Income$987.00M
Interest Expense$173.35M
Net Income$471.00M
EPS (Basic)$2.95
EPS (Diluted)$2.92
Shares Outstanding (Basic)159.00M
Shares Outstanding (Diluted)160.00M

Key Highlights

  • 1Net revenues increased by 1.9% to $7.51 billion in 2011, aided by the acquisitions of Athena Diagnostics and Celera Corporation.
  • 2Income from continuing operations significantly decreased by 34.7% to $472.1 million, primarily due to a $236 million pre-tax charge related to the settlement of a California lawsuit and other restructuring costs.
  • 3The company made significant strategic acquisitions in 2011, acquiring Athena Diagnostics for $740 million and Celera Corporation for $344 million, expanding its diagnostic capabilities.
  • 4Operating income decreased by 4.4% to $995.0 million, reflecting the impact of one-time charges and increased operating expenses.
  • 5Total debt increased to $4.02 billion, largely due to financing activities for acquisitions and share repurchases.
  • 6The company announced a multi-year program to reduce its cost structure by $500 million by the end of 2014.
  • 7Quest Diagnostics increased its quarterly common stock dividend by 70% in January 2012, signaling confidence in future cash flows.

Frequently Asked Questions

The main drivers for Quest Diagnostics in 2011 were the strategic acquisitions of Athena Diagnostics and Celera Corporation, which boosted net revenues. However, profitability was significantly impacted by a $236 million pre-tax charge to settle a California lawsuit, alongside other restructuring and integration costs that led to a substantial decrease in income from continuing operations.

The acquisitions of Athena Diagnostics and Celera Corporation contributed positively to net revenues, with Athena and Celera adding 2.2% to consolidated revenue growth. However, these acquisitions also resulted in significant transaction costs in 2011, totaling approximately $20 million, which impacted earnings. Goodwill and intangible assets on the balance sheet increased substantially due to these acquisitions.

Quest Diagnostics has launched a multi-year program targeting $500 million in cost reductions by the end of 2014, focusing on standardizing processes, increasing automation, and centralizing activities. The company plans to invest in smaller acquisitions, research and development, and technology to improve quality and efficiency, while also prioritizing debt reduction and returning capital to shareholders through dividends and share repurchases.

Quest Diagnostics believes the diagnostic testing industry has strong long-term fundamentals, driven by an aging population and advancements in genomics. Despite current economic pressures and reimbursement challenges, the company is well-positioned to benefit from industry growth due to its leading market position and strategic investments.